Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief medication Journavx, which was approved to much fanfare by the FDA two weeks ago.